Abaloparatide (Tymlos) Dosing for a 68-Year-Old Male with Osteoporosis
The recommended dose of Tymlos (abaloparatide) for this 68-year-old male with osteoporosis is 80 mcg administered subcutaneously once daily. 1
Administration Details
- Route: Subcutaneous injection into the periumbilical region of the abdomen
- Frequency: Once daily at approximately the same time each day
- Duration: Treatment should not exceed 2 years during the patient's lifetime
- First dose: Should be administered where the patient can sit or lie down in case of orthostatic hypotension
- Injection site: Rotate daily
Supplementation Requirements
- Calcium: 1,000-1,200 mg daily (dietary and supplemental combined)
- Vitamin D: 800-1,000 IU daily (target serum 25-OH vitamin D level of ≥30-50 ng/mL)
- Baseline serum calcium testing should be performed before initiating therapy
Treatment Considerations
Efficacy in Male Patients
Abaloparatide has demonstrated significant efficacy in men with osteoporosis. In the ATOM study, men treated with abaloparatide for 12 months showed:
- 8.48% increase in lumbar spine BMD
- 2.14% increase in total hip BMD
- 2.98% increase in femoral neck BMD 2
Treatment Duration
- Maximum treatment duration: 2 years
- After completing abaloparatide treatment, transition to an antiresorptive agent is recommended to maintain bone density gains 1
Monitoring
- Baseline serum calcium and vitamin D levels before starting therapy
- BMD measurement at baseline and periodically during treatment
- Monitor for potential adverse effects, particularly orthostatic hypotension with initial doses
Contraindications and Precautions
Abaloparatide should be avoided in patients with:
- History of systemic hypersensitivity to abaloparatide
- Open epiphyses
- Metabolic bone diseases other than osteoporosis (e.g., Paget's disease)
- Bone metastases or history of skeletal malignancies
- Prior radiation therapy involving the skeleton
- Hereditary disorders predisposing to osteosarcoma 1
Common Adverse Effects
The most common adverse effects reported in clinical trials include:
- Injection site reactions
- Dizziness
- Nasopharyngitis
- Arthralgia
- Hypertension
- Headache 2
Practical Administration Tips
- Visually inspect solution before administration (should be clear and colorless)
- Do not use if solution appears cloudy or contains particles
- Do not administer intravenously or intramuscularly
- Proper training on injection technique is essential
- Store pen in refrigerator when not in use
- Discard pen after 30 days even if solution remains
Abaloparatide is an effective anabolic treatment option for men with osteoporosis, with a safety profile consistent with previous studies in postmenopausal women 2. Real-world data shows that approximately 65% of patients complete the prescribed treatment course, with financial concerns and tolerability being the most common reasons for discontinuation 3.